antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»antibiotics-391Research ArticleОБЗОРЫREVIEWSОпыт эмпирического лечения тяжёлого острого респираторного синдрома, вызванного коронавирусом IV генотипа Никитин А. В. ЦефтаролExperience with Empirical Treatment of Severe Acute Respiratory Syndrome Due to Coronavirus, Genotype IVЩукинаВ. Н.ShchukinaV. N.noemail@neicon.ruЛогиноваС. Я.LoginovaS. Ya.noemail@neicon.ruБорисевичС. В.BorisevichS. V.noemail@neicon.ruБондаревВ. П.BondarevV. P.noemail@neicon.ruФилиал федерального государственного учреждения «48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации - «Вирусологический центр»Russian Federation201113052020567-84246Copyright © ООО «Издательство ОКИ», 20202020ООО «Издательство ОКИ»ООО «Издательство ОКИ»https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNoticehttps://www.antibiotics-chemotherapy.ru/jour/article/view/391

Обобщен зарубежный опыт эмпирического лечения тяжёлого острого респираторного синдрома (ТОРС, SARS), обусловленного коронавирусом IV генотипа. Отмечено, что данные об эффективности рибавирина в отношении ТОРС у людей противоречивы. Доказана эффективность в очагах ТОРС двух химиопрепаратов: лопинавира и ритонавира, используемых в настоящее время при ретровирусной терапии инфицированных ВИЧ в мире. Поиск эффективных отечественных неспецифических медицинских средств защиты в отношении ТОРС является актуальным.

Foreign experience with empirical management of severe acute respiratory syndrome (SARS) due to coronavirus, genotype IV is described. It is indicated that the data on the efficacy of ribavirin with respect to SARS in the patients are contradictory. The efficacy of two chemotherapeutics, i. e. lopinavir and ritonavir used in the SARS foci is confirmed. The drugs are at present applicable all over the world in retrovirus therapy of HIV infected subjects. The search for efficient Russian unspecific medicines for control of SARS is actual.

тяжёлый острый респираторный синдромпротивовирусная активностьхимиотерапия коронавирусной инфекциирибавиринлопинавирритонавирsevere acute respiratory syndromeantiviral activitycoronavirus infectionchemotherapyribavirinlopinavirritonavirReferencesWorld Health Organization: http://www. WHO.int/csr/sars/en/index.html.World Health Organization: http://www. WHO.int/csr/sars/en/index.html.www.minzdrav-rf.ru (Пресс-релиз от 24.06.03 г. Госсанэпиднадзора России).www.minzdrav-rf.ru (Пресс-релиз от 24.06.03 г. Госсанэпиднадзора России).Онищенко Г.Г., Васильев Н.Т., Максимов В.А. и др. Выделение и идентификация возбудителя тяжёлого острого респираторного синдрома от больных атипичной пневмонией. ЖМЭИ 2003; 5: 109-112.Онищенко Г.Г., Васильев Н.Т., Максимов В.А. и др. Выделение и идентификация возбудителя тяжёлого острого респираторного синдрома от больных атипичной пневмонией. ЖМЭИ 2003; 5: 109-112.Патент на штамм СоД вируса тяжёлого острого респираторного синдрома рода Coronavirus, предназначенный для разработки средств и методов биологической защиты № 2003136244. Заявление о выдаче патента РФ на изобретение подано в Российское агентство по патентам и товарным знакам 17 декабря 2003 г.Патент на штамм СоД вируса тяжёлого острого респираторного синдрома рода Coronavirus, предназначенный для разработки средств и методов биологической защиты № 2003136244. Заявление о выдаче патента РФ на изобретение подано в Российское агентство по патентам и товарным знакам 17 декабря 2003 г.Wang J.-T., Sheng W.-H., Fang C.-T. et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis 2004; 10: 5: 818-824.Wang J.-T., Sheng W.-H., Fang C.-T. et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis 2004; 10: 5: 818-824.Hsueh P.-R., Chen P.-J., Hsiao C.H. et al. Patient data, early SARS epidemic, Taiwan. Ibid 2004; 10: 3: 489-493.Hsueh P.-R., Chen P.-J., Hsiao C.H. et al. Patient data, early SARS epidemic, Taiwan. Ibid 2004; 10: 3: 489-493.Zhaori G. Antiviral treatment of SARS: can we draw any conclusions?. CMAJ 2003; 169: 11: 549-551.Zhaori G. Antiviral treatment of SARS: can we draw any conclusions?. CMAJ 2003; 169: 11: 549-551.Zhao Z., Zhang F., Xu M. et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003; 52: 715-720.Zhao Z., Zhang F., Xu M. et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003; 52: 715-720.Chu C.M., Cheng V.C.C., Hung I.F.N. et al. Role of lopinavir/ritonavir treatment of SARS: initial virological and clinical findings. Thorax 2004; 59: 252-256.Chu C.M., Cheng V.C.C., Hung I.F.N. et al. Role of lopinavir/ritonavir treatment of SARS: initial virological and clinical findings. Thorax 2004; 59: 252-256.Chan J.W.M., Ng C.K., Chan Y.H. et al. Short-term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 2003; 58: 686-689.Chan J.W.M., Ng C.K., Chan Y.H. et al. Short-term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 2003; 58: 686-689.Hsu L.-Y., Lee C.-C., Green J.A. et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 2003; 9: 6: 731-737.Hsu L.-Y., Lee C.-C., Green J.A. et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 2003; 9: 6: 731-737.Poutanen S.M., Low D.E., Henry B. et al. Identification of severe acute respiratory syndrome in Canada. Thorax 2003; 348: 20: 1995-2005.Poutanen S.M., Low D.E., Henry B. et al. Identification of severe acute respiratory syndrome in Canada. Thorax 2003; 348: 20: 1995-2005.Avendano M., Derkach P., Swan S. Clinical course and management of SARS in health care workers in Toronto: a case series. Canad Med Associat J 2003; 168: 13: 1649-1660.Avendano M., Derkach P., Swan S. Clinical course and management of SARS in health care workers in Toronto: a case series. Canad Med Associat J 2003; 168: 13: 1649-1660.Booth C.M., Matukas L.M., Tomlinson G.A. et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003; 289: 21: 2801-2809.Booth C.M., Matukas L.M., Tomlinson G.A. et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003; 289: 21: 2801-2809.Chan K.S., Lai S.T., Chu C.M. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003; 9: 399-406.Chan K.S., Lai S.T., Chu C.M. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003; 9: 399-406.Lee N., Hui D., Wu A. et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. New Engl J Med 2003; 348: 1986-1994.Lee N., Hui D., Wu A. et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. New Engl J Med 2003; 348: 1986-1994.Tsang K.W., Ho P.L., Ooi G.C., Yee W.K. et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. New Engl J Med 2003; 348: 20: 1977-1985.Tsang K.W., Ho P.L., Ooi G.C., Yee W.K. et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. New Engl J Med 2003; 348: 20: 1977-1985.Tsang K.W., Lam W.K. Management of severe acute respiratory syndrome. Amer J Resp Crit Care Med 2003; 168: 417-424.Tsang K.W., Lam W.K. Management of severe acute respiratory syndrome. Amer J Resp Crit Care Med 2003; 168: 417-424.Sung J.J.Y., Wu A., Joynt G.M. et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004; 59: 414-420.Sung J.J.Y., Wu A., Joynt G.M. et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004; 59: 414-420.Wang J.T., Wang J.L., Fang C.T., Chang S.C. Early defervescence and SARS recovery. Emerg Infect Dis 2004; 10: 3: 544-545.Wang J.T., Wang J.L., Fang C.T., Chang S.C. Early defervescence and SARS recovery. Emerg Infect Dis 2004; 10: 3: 544-545.Peiris J.S.M., Chu C.M., Cheng V.C.C. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361: 1767-1772.Peiris J.S.M., Chu C.M., Cheng V.C.C. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361: 1767-1772.Zhao Z., Zhang F., Xu M. et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003; 52: 715-720.Zhao Z., Zhang F., Xu M. et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003; 52: 715-720.Avendano M., Derkach P., Swan S. Clinical course and management of SARS in health care workers in Toronto: a case series. Canadian Medical Association J 2003; 168: 13: 1649-1660.Avendano M., Derkach P., Swan S. Clinical course and management of SARS in health care workers in Toronto: a case series. Canadian Medical Association J 2003; 168: 13: 1649-1660.Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. WHO > WHO sites > CSR Home > Severe acute respiratory syndrome (SARS) > Cumulative number of reported probable cases of severe acute respiratory syndrome (SARS).Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. WHO > WHO sites > CSR Home > Severe acute respiratory syndrome (SARS) > Cumulative number of reported probable cases of severe acute respiratory syndrome (SARS).Tsang O.T.Y., Chau T.N., Choi K.-W. et al. Severe acute respiratory syndrome: relapse? Hospital infection? Emerg Infect Dis 2003; 9: 9: 1180-1181.Tsang O.T.Y., Chau T.N., Choi K.-W. et al. Severe acute respiratory syndrome: relapse? Hospital infection? Emerg Infect Dis 2003; 9: 9: 1180-1181.Severe acute respiratory syndrome (SARS) and coronavirus testing. United States, 2003. Weekly 2003; 52: 14: 297-302.Severe acute respiratory syndrome (SARS) and coronavirus testing. United States, 2003. Weekly 2003; 52: 14: 297-302.Ward S.E., Loutfy M.R., Blatt L.M. et al. Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroids. Antivir Ther 2005; 10: 2: 263-275.Ward S.E., Loutfy M.R., Blatt L.M. et al. Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroids. Antivir Ther 2005; 10: 2: 263-275.Chan J.W.M., Lee S. SARS patients and need for treatment. Emerg Infect Dis 2004;10: 10: 1877-1878.Chan J.W.M., Lee S. SARS patients and need for treatment. Emerg Infect Dis 2004;10: 10: 1877-1878.

The authors declare that there are no conflicts of interest present.